Investor Transition Histories and the Timing of Follow-on Investor Entry in Early-Stage Healthcare Ventures
This study of 744 early-stage healthcare ventures reveals that an investor's history of successfully transitioning within the same financing category significantly increases the likelihood of follow-on investor entry during the second and third years of a venture's development, whereas such category-linked experience shows weaker or different effects in the first year.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every new company is a story of survival, but for those in healthcare, the plot is often written in stages. These ventures do not simply ask for money once; they must prove their worth repeatedly to different groups of backers. First, a small team of investors might provide the initial cash to build a prototype or run early tests. Later, as the company grows and faces new hurdles like clinical trials or regulatory approval, it needs fresh capital. At that point, a new investor might step in, bringing not just money but also a vote of confidence that can help the company survive its next chapter. The timing of this new investor's arrival is critical. If they come too early, the company may lack the proof needed to justify the risk. If they come too late, the company might run out of cash before it can reach its next milestone. The central question for researchers is whether the past experiences of the very first investors can predict when a new backer will arrive, and if the type of experience matters more at some times than others.
A study published in 2026 by Hana Kim of the Korea Advanced Institute of Science and Technology explores this exact dynamic within the healthcare sector. The research focuses on 744 early-stage healthcare companies that received their first private funding between 2011 and 2024. The author tracked these companies to see when a new investor, someone who was not part of the original group, decided to join the team. To understand what might influence this timing, the study looked closely at the history of the initial investors. Specifically, it distinguished between two types of past successes. One type is "category-linked" experience, where an investor has previously helped a company in the same specific field—such as biopharmaceuticals or medical devices—grow from an early stage to a later, more mature stage. The other type is "outside-category" experience, where an investor has helped companies succeed, but those companies were in different fields entirely.
The analysis reveals that the value of an investor's history changes as the venture ages. In the first year after a company receives its initial funding, the presence of investors with broad, outside-category experience is slightly more associated with the arrival of a new backer, although this early difference is sensitive to statistical adjustments. However, as time passes, the pattern shifts. By the third and fourth years (months 25–60), the advantage flips. Investors who have successfully guided companies through similar, specific fields become much more likely to see a new investor join their current venture. The data shows that for companies in their third and fourth years, having an initial investor with a history of success in the same specific category increases the rate at which new investors enter by roughly 55 percent in the third year and nearly 90 percent in the fourth year, compared to those without such a history.
This finding suggests that the relevance of an investor's past is not static. Early on, a general track record of finding successful companies might be enough to signal quality to new backers. But as a healthcare venture matures and faces the complex, specific challenges of its own industry—such as navigating drug approval processes or proving the efficacy of a new device—the specific, shared experience of the initial investors becomes far more valuable. It appears that new investors look for proof that the current team understands the unique hurdles of their specific field, and they find that proof in the detailed history of their initial backers.
The study also considered whether the size of the initial investment or the specific type of healthcare company, such as whether it was a biopharmaceutical firm, changed these results. The analysis found that the timing of the new investor's entry was not significantly different based on whether the company was in biopharma or another health sector, nor did the amount of money raised initially fully explain the delay or speed of the next funding round. While the researchers could not prove that the investors' history directly caused the new funding to arrive—since investors and companies choose each other based on many hidden factors—the statistical patterns were strong and consistent across different checks. The results suggest that the story of a company's financing is not just about how much money it has, but about the specific journey its first supporters have walked before. For entrepreneurs and investors alike, the lesson is that the right kind of experience matters most when the venture is deep in the work of proving its value, not just at the very beginning.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.